Ìý˵£¬±ïÆø30Ã룬¿ÉÒÔÅжÏÄãµÄ·ÎÊÇ·ñ¿µ½¡¡£
¿ìÀ´¼ì²âһϣ¡ÏÖÔÚ£¬×îÏȱïÆø£¬Ö±µ½Ô²µã´ÓAµãµÖ´ïBµã¡£
(ͼƬÀ´×ÔÍøÂç)
ʲô£¿Ã»Óмá³Öµ½30Ã룡
ÄÇÎÒºÜÒź¶µÄ¸æËßÄú£¬Õâ¸öЧ¹û²¢²»¿ÉÕæʵ·´Ó¦ÄúµÄ·Î²¿¿µ½¡×´Ì¬£¨¶¥¹øÅÜ£©~Ö»ÄÜ˵Ã÷£¬ÄúµÄ·Î»îÁ¿½ÏС£¬ÊDz»ÊÇÁ¼¾ÃûÔ˶¯À²£¿
ËäÈ»ÕâÒ»²âÊÔÎÞ·¨ÅжϷεĿµ½¡×´Ì¬£¬µ«ÄãÊÇ·ñ¸ÐÊܵ½Á˺ôÎüµÄÖ÷ÒªÐÔ¡£Ê±Ê±¿Ì¿Ì£¬ÐÂÏʵĿÕÆøÕýͨ¹ýÆø¹Ü½øÈëÎÂůµÄÐØÇ»£¬ÆäÖеÄÑõÆø´Ó·ÎÖÐÂ˳ö£¬Ëæ×ÅѪҺ±¼Ïò´óÄÔ£¬ËÄÖ«¡
½ñÌ죬ÎÒÃDZãÀ´ÏÈÈÝÏÂÈËÌåºôÎüÖÐÊࡪ¡ª·Î£¬Ö÷Òª°üÀ¨ËüµÄ½á¹¹£¬Ï¸°ûÀàÐÍ£¬Ïà¹ØÖØ´ó¼²²¡¼°¶¯ÎïÄ£×Ó¡£
·ÎµÄÐÄÀí½á¹¹
Õý³£µÄ·Î³ÊdzºìÉ«£¬Î»ÓÚÐØÇ»£¬ÁýÕÖÔÚÐÄÔàÖ®ÉÏ¡£×óÓÒÐØÇ»¸÷ÓзÎÒ¶£¬×ó¶þÓÒÈý£¬ÓҷοÉÒÔ·ÖΪÉÏ¡¢ÖС¢ÏÂÈýÒ¶£¬×ó·ÎÔò½öÓÐÉÏ¡¢ÏÂÁ½Ò¶£¬ÒÔÊÇÈËÌåµÄ·ÎÒ»¹²ÓÐÎåÒ¶¡£Ã¿¸ö·ÎÒ¶Ö®¼äÓÐÐØĤÀë¸ô£¬¸÷×ÔÓÐÖ§Æø¹ÜÓëÖ÷Æø¹ÜÏàͨ£¬Ï໥֮¼äûÓÐÁªÏµ¡£
ÿ´ÎºôÎü£¬¿ÕÆøͨ¹ý±ÇÇ»½øÈëÆø¹Ü£¬ÔÙ½øÈëÖ§Æø¹Ü¡£Ö§Æø¹Ü·ÖΪ×óÓÒÖ÷¸ÉÖ§Æø¹Ü£¬Æä×é³ÉÓëÆø¹ÜÏàËÆ£¬²¢Öð½¥·ÖÖ¦³É¸üСµÄ·ÖÖ§¡ª¡ªÆø¹ÜÖ§Æø¹ÜÊ÷£¬¶ÔÎüÈëµÄ¿ÕÆø¾ÙÐÐÖ¸µ¼¡¢¼ÓʪºÍ¼ÓÈÈ¡£ÖÕÄ©Ö§Æø¹Ü×îºóÐγÉС·ÎÅÝ´Ø£¬·ÎÅÝ×ÜÊýµÖ´ïÊý°ÙÍò¡£·ÎÅݱ»Ã«Ï¸Ñª¹ÜÍøËùÀ§ÈÆ¡£Í¨¹ýëϸѪ¹ÜµÄ±¡Ä¤£¬¿ÕÆøºÍѪҺ¾ÙÐÐÑõÆøºÍ¶þÑõ»¯Ì¼µÄ½»Á÷[1]¡£
ͼ1 ºôÎüϵͳʾÒâͼ(Òý×Ôhttps://www.nhlbi.nih.gov/health-topics/how-lungs-work)
·ÎµÄϸ°û·ÖÐÍ
·Î²¿Ï¸°ûÊÇ·ÎÖ´ÐÐÐÄÀí¹¦Ð§µÄ»ù±¾µ¥Î»£¬Í¨¹ýÏàʶÆäÖÖÀàºÍ״̬£¬ÈËÃÇ¿ÉÒÔ½øÒ»²½Ñо¿·Î²¿¼²²¡µÄ±¬·¢ÆøÀí£¬¾ÙÐÐ׼ȷÓÐÓõÄÖÎÁÆ¡£Í¨¹ýÏÔ΢¾µÊӲ죬ÃâÒßÓ«¹â±ê¼ÇµÈ¹Å°åÒªÁ죬ÒÑÖªÏþµÄÈËÌå·Î²¿Ï¸°ûÀàÐÍÓÐ45ÖÖ¡£¶ø¿Æѧ¼Ò½èÖú¸Õ¸ÕÐËÆðµÄµ¥Ï¸°û²âÐòÊÖÒÕ£¬´ÓÁíÒ»¸öά¶È»æÖƳöÈËÌå¸ü¶àµÄ·Î²¿Ï¸°ûÖÖÀ༰±í´ï״̬£¬È·¶¨Á˳ÉÈË·ÎÖÐÓÐ58ÖÖת¼Éϲî±ðµÄϸ°ûȺÌ壬°üÀ¨15ÖÖÉÏƤϸ°û£¬9ÖÖÄÚƤϸ°û£¬9ÖÖ»ùÖÊϸ°û£¨Í¼2£©ºÍ25ÖÖÃâÒßϸ°û(ͼ3)[2]¡£
ͼ2 ·Î²¿ÉÏƤϸ°û¡¢ÄÚƤϸ°ûºÍ»ùÖÊϸ°ûȺ·ÖÀ༰×é֯ѧ¶¨Î»[2]
¶ø¹éÄɳöµÄÕâ58ÖÖϸ°ûÖаüÀ¨41ÖÖÒÑÖªµÄ·Î²¿Ï¸°ûÀàȺ£¬²»°üÀ¨Ô±¾±»ÒÔΪ±£´æµÄ4ÖÖϸ°û£¬¼´Éñ¾Ôª¡¢Éñ¾½ºÖÊ£¬´Ø״ϸ°ûÒÔ¼°ÊÈËáÁ£Ï¸°û¡£¶Ô¸ÃÑо¿Ð§¹û¸ÐÐËȤµÄСͬ°é¿ÉÒÔÔÚ¹«ÖÚºÅÖÐË÷ÒªÔÎÄ¡£ÏÂÃ潫ÌôÑ¡Á½´óÀຬÁ¿×î¶àµÄ·Î²¿Ï¸°û£¨ÉÏƤϸ°ûºÍÄÚƤϸ°û£©×ö¼òÒªÏÈÈÝ¡£
ͼ3 ·ÎÃâÒßϸ°û·ÖȺ[2]
·ÎÅÝÉÏƤϸ°û
·ÎÅÝÉÏƤϸ°û×÷ΪÆøÌå½»Á÷µÄµ¥Î»£¨Í¼4£©£¬Î¬³Ö×Å·ÎÔàµÄ»ù±¾¹¦Ð§¡£·ÎÅÝÉÏƤϸ°ûÖ÷ÒªÓÉIÐÍ·ÎÅÝÉÏƤϸ°û£¬¢òÐÍ·ÎÅÝÉÏƤϸ°û×é³É¡£
·ÎÅÝIÐÍϸ°û£¬ÆäÍâò±ê¼ÇÎïÊÇˮͨµÀÂÑ°×5(AQP5)Õ¼·ÎÅÝÍâò»ýµÄ96%¡£ÕâЩϸ°ûºÜÊDZ¡£¬³ÊÁÛ×´£¬ËüÃÇÓë·ÎëϸѪ¹ÜÄÚƤ¹²ÓÃÒ»¸ö»ùµ×Ĥ£¬ÐγÉÆøѪÆÁÕÏ£¬Ôڴ˱¬·¢ÆøÌå½»Á÷¡£
ͼ4 СÊó·ÎÅÝÇøʾÒâͼ[4]
IIÐÍϸ°ûΪÇòÐηÎϸ°û£¬ÆäÍâò±ê¼ÇÎïΪSFTPC£¨ÓÖ³ÆΪSPC£©£¬½öÕ¼·ÎÅÝÍâò»ýµÄ4%£¬µ«Õ¼·ÎÅÝÉÏƤϸ°ûµÄ60%£¬Õ¼ËùÓзÎϸ°ûµÄ10-15%¡£¢òÐÍ·ÎÅÝϸ°ûλÓÚ·ÎÅݹսǴ¦£¬¾ßÓкϳɡ¢Éø͸·ÎÍâò»îÐÔÎïÖʵĹ¦Ð§£¬»¹¿Éµ÷Àí·ÎÅÝË®·Ö£¬¼æÓзֽâ³ÉIÐÍϸ°ûµÄ×÷ÓÃ[3]¡£
·Î²¿ÄÚƤϸ°û
ÄÚƤϸ°ûλÓÚÉø͸Ôڷβ¿µÄѪ¹ÜÉÏ£¬Ëü²»µ«ÊÇѪҺ£¬¿ÕÆøºÍ»ùÖÊ×éÖ¯Ö®¼äµÄÎïÀíÆÁÕÏ£¬»¹¾ßÓдúл»îÐÔ£¬¼ÓÈëÑ×Ö¢¿ØÖÆ¡¢°×ϸ°ûÔËÊ䡢Ѫ¹ÜÌìÉúºÍѪ¹ÜÕÅÁ¦µÈÀú³Ì¡£Æ¾Ö¤×îеĵ¥Ï¸°û²âÐòЧ¹û£¬·ÎÔàÄÚƤϸ°û¿É·ÖΪÁÜ°ÍÄÚƤϸ°û¡¢¶¯ÂöÄÚƤϸ°û¡¢Í¨Ë×ëϸѪ¹ÜÄÚƤϸ°û(General capillary, gCap )¡¢Æø¹Üϸ°û(Aerocyte)¡¢·Î¾²ÂöÄÚƤϸ°ûºÍÈ«Éí¾²ÂöÄÚƤϸ°û[5]¡£
ÆäÖУ¬¼ÓÈëÆøÌå½»Á÷µÄÊÇ·ÎÅÝëϸѪ¹ÜÄÚƤϸ°û£¬ÓÉ¡°Æø¹Üϸ°û¡±ºÍͨË×ëϸѪ¹ÜÄÚƤϸ°ûÅäºÏ×é³É¡£¡°Æø¹Üϸ°û¡±×¨ÃÅÓÃÓÚÆøÌå½»Á÷ºÍ°×ϸ°ûÔËÊ䣬ÊǷζÀÍ̵ÄÄÚƤϸ°û£»Í¨Ë×ëϸѪ¹ÜÄÚƤϸ°ûÓÃÓÚµ÷ÀíѪ¹ÜÊæËõÕÅÁ¦£¬²¢ÔÚëϸѪ¹ÜÎÈ̬ºÍÐÞ¸´Öг䵱¸Éϸ°û/×æϸ°û£¨Í¼5£©[6]¡£
ͼ5 ·ÎÅÝÆøÌå½»Á÷ʾÒâͼ[6]
ÄÏÄ£ÉúÎïÔÚСÊó·Î²¿Ï¸°ûÌض¨marker»ùÒòÖÐÇÃÈëCre/DreÖØ×éøԪ¼þ»ò±¨¸æ»ùÒò£¬Ñо¿Õß¿ÉÒÔ¶ÔÿÀàϸ°û¾ÙÐбê¼Ç£¬»¹¿ÉÒÔÔÚÌض¨Ï¸°ûȺÀï¾ÙÐлùÒò¼°Ï¸°û¹¦Ð§µÄÑо¿¡£Ïêϸģ×ÓÐÅÏ¢¼ûÏÂ±í£º
±í1 ·Î²¿Ìض¨Ï¸°û¹¤¾ßÊó
×÷ΪÖ÷ÒªµÄºôÎüÆ÷¹Ù£¬·Î²¿Ëæʱ»áÇÖÈëϸ¾ú¡¢²¡¶¾¡¢Õæ¾ú¡¢»Ò³¾µÈ£¬Ôì³É²î±ðÀàÐ͵ķβ¿¼²²¡£¬ÈçйڷÎÑ×£¬´óÒ¶ÐÔ·ÎÑ×£¬Ö§Æø¹ÜÑ׵ȣ¬ÑÏÖصĿɵ¼Ö¼±ÐÔ»òÂýÐÔºôÎüË¥½ß¼°ÖÖÖַΰ©¡£ÏÖÔÚ£¬ÈËÃǶÔÕâЩ¼²²¡·¢²¡»úÖÆ»¹²»·óÏàʶ£¬Òò´ËÖÎÁƲ½·¥Ê®·Öȱ·¦¡£ÎªÉîÈëÑо¿¼²²¡µÄ±¬·¢Éú³¤£¬Ïà¹ØÑо¿¶¯ÎïÄ£×ӵĹ¹½¨ÊDZز»¿ÉÉÙµÄÒ»»·¡£
йڷÎÑ×Ñо¿Ä£×Ó
×ÔйÚÒßÇ鱬·¢ÒÔÀ´£¬×èÖ¹2021Äê11ÔÂ8ÈÕ£¬È«ÇòйڷÎÑ×ÀÛ¼ÆÈ·ÕﲡÀýÒѾÁè¼Ý2.5ÒÚÀý£¬È«ÇòÀÛ¼ÆéæÃü²¡ÀýÁè¼Ý505ÍòÀý¡£
ACE2 ÊÇ´Ë´Îйڲ¡¶¾Ñ¬È¾ÈËÌåµÄÖ÷Ҫ͎áÊÜÌ塣йڲ¡¶¾µÄ´ÌÍ»ÌÇÂѰ׿ÉÒÔÓë·ÎÉÏƤϸ°ûϸ°ûĤÉ쵀 ACE2ÌØÒìÐÔµÄÍŽᡣͨ¹ýÖ¬ÖÊ°ûĤµÄÄÚÍÌ×÷Ó㬲¡¶¾¿ÅÁ£ÓëÄÒÅÝÈںϲ¢¿ìËÙ½øÈëËÞÖ÷ϸ°ûÄÚ[7]¡£µ«Ð¡Êóϸ°û²»¾ßÓÐÍŽáйڲ¡¶¾ÂÑ°×µÄÄÜÁ¦£¬Òò´Ë¿ÉÒÔ½«ÈËACE2µÄתÈ뵽СÊóÌåÄÚ£¬ÕâÖÖСÊóѬȾSARS-CoV-2ºóµÄ³¦µÀ¡¢·ÎÑ×Ö¢×´¼°²¡ÀíѧÌØÕ÷ÓëCOVID-19»¼ÕߺÜÏàËÆ[8]¡£ÄÏÄ£ÉúÎï×ÔÖ÷Ñз¢ÁËCAG-hACE2-IRES-Luc-Tg(hACE2-Tg) СÊ󣬿ÉÒÔ×÷ΪÒßÃçºÍÒ©ÎïÑз¢µÄÖ÷Òª¹¤¾ß¡£ÏêϸÏÈÈݿɼûÍùÆÚÍÆÎÄ£ºÑ¬È¾²¡Ñо¿É±ÊÖﵡª¡ª³£Óö¯ÎïÄ£×ÓÏÈÈÝ
ÂýÐÔÛÕ±ÕÐÔ·ÎÑ×Ñо¿Ä£×Ó
ÂýÐÔÛÕ±ÕÐÔ·ÎÑ×£¨chronic obstructive pulmonary emphysema£¬COPD£©ÓÖ³ÆÛÕ±ÕÐÔ·ÎÆøÖ×£¬¾ßÓÐÖÕĩϸ֧Æø¹ÜÔ¶¶Ë²¿·Ö£¨°üÀ¨ºôÎüÐÔϸ֧Æø¹Ü¡¢·ÎÅݹܡ¢ ·ÎÅÝÄҺͷÎÅÝ£©ÅòÕÍ£¬²¢°éÓÐÆøÇ»±ÚµÄÆÆËðµÄÌåÏÖ¡£ÏÖÔÚ£¬ÎÒ¹úÂý×è·Î»¼ÕßÈËÊýÔ¼1ÒÚ£¬ÒѾ³ÉΪÓë¸ßѪѹ¡¢ÌÇÄò²¡¡°»ìΪһ̸¡±µÄÂýÐÔ¼²²¡£¬×é³ÉÖØ´ó¼²²¡¼ç¸º[9]¡£
ͼ6 Õý³£µÄ·ÎÅݺÍËðÉ˺óµÄ·ÎÅݱÈÕÕͼ£¬ËðÉ˺óµÄ·ÎÅÝʧȥµ¯ÐÔ²¢Ì«¹ýÅòÕÍ(ͼƬÀ´×ÔÍøÂç)
ͨÀýCOPDÓÕµ¼Ä£×Ó
ÏÖÔÚ×î³£ÓõÄCOPD¶¯ÎïÄ£×ÓÊÇСÊó¡£Í¨¹ýÔÚÏãÑÌÑÌÎíÖÐ̻¶ 6¸öÔ£¬Ð¡ÊóÏÔʾ³öÈËÀàCOPDµÄһЩÌØÕ÷£¬ÈçÂýÐԷβ¿Ñ×Ö¢¡¢ÖжÈÆøµÀÀ©ÔöºÍÇá¶ÈСÆøµÀÏËά»¯[10]¡£±ðµÄ£¬Í¨¹ýµ¯ÐÔÂÑ°×ø¾ÙÐÐÆø¹ÜµÎ×¢¡¢Î¢ÉúÎï¼°Æä²úÆ·ÓÕµ¼»òÕßÆäËû»¯Ñ§ÎïÖÊÓÕµ¼£¬Ò²Óй¹½¨ÀֳɵÄÏÈÀý[11]¡£
»ùÒòÐÞÊÎCOPD×Ô¾õÄ£×Ó
Ëæ×Å»ùÒòÐÞÊÎÊÖÒÕµÄÉú³¤£¬Í¨¹ýµ÷¿ØCOPDÏà¹Ø»ùÒòµÄ±í´ï£¬½¨Éè»ùÒò¹¤³ÌСÊóÄ£×ÓµÄÓ¦ÓóÊÉÏÉýÇ÷ÊÆ¡£Íâò»îÐÔ¼ÁÂÑ°×(Surfactant protein, SP)-DÊÇÒ»ÖÖģʽʶ±ð·Ö×Ó£¬ÊôÓÚ½ºÔÄý¼¯ËØÂÑ°×¼Ò×å¡£SP-DµÄÖ÷Òª¹¦Ð§ÊÇÍŽᲡÔ΢ÉúÎï»òÕß¼ÄÉú³æ£¬ÕâЩÉúÎïͨ¹ýµ÷Àí×÷Óñ»ÖÐÐÔÁ£Ï¸°ûɨ³ý£¬´Ó¶ø±»ÍÌÊÉϸ°ûʶ±ð¡£ÁÙ´²Öз¢Ã÷¾ßÓнϸߵÄSP-DˮƽµÄ»¼Õߣ¬ÆäÒòCOPD±¬·¢µÄΣº¦½ÏµÍ£¬·Î¹¦Ð§Ï½µËÙÂʽϻºÂý¡£Sftpd»ùÒò£¨±àÂëSP-DÂÑ°×£©ÇóýСÊó¿É·ºÆð·ÎÆøÖס¢¾ÙÐÐÐÔ¸ôĤ±Úºñ¶ÈºÍÐØĤÏÂÏËά»¯£¬ÌáÐÑÕâЩ¶¯Îï·ºÆð·ÎÄÚ·ÎÆøÖ׺ÍÏËά»¯µÄÍŽá±íÐÍ[12]¡£
COPD°ÐµãÑо¿Ä£×Ó
IL-17aÊÇCOPDÖÐÐÔÁ£Ï¸°ûÆøµÀÑ×Ö¢µÄÒªº¦½éÖÊ¡£Éý¸ßµÄѪÇåIL-1¦ÂºÍ IL-17aˮƽ¿É×÷ΪCOPDÒ»Á¬ÐÔÖÐÐÔÁ£Ï¸°ûÆøµÀÑ×Ö¢ºÍDZÔÚÒ»Á¬¶ñ»¯µÄÉúÎï±ê¼ÇÎï¡£×è¶ÏIL17a/IL17RA¿ÉÓÐÓýµµÍÏãÑÌÑÌÎíÓÕµ¼µÄMUC5ACÂѰס¢IL6¡¢TNF¦ÁºÍIL-1¦ÂµÈÑ×Ö¢Òò×ÓÔÚÖ§Æø¹ÜÉÏƤϸ°ûÖеıí´ï¡£ÔÚСÊóÌåÄÚÌØÒìÐÔÇóýIL17aÔòÓÐÒæÓÚïÔÌÖÐÐÔÁ£Ï¸°ûÏòÆøµÀµÄÕÙļ[13]¡£ÕâЩЧ¹ûÌáÐÑ°ÐÏòIL17aÊÇDZÔÚµÄCOPDÖÎÁÆÊֶΡ£
COPD»¼Õß³ýÁËÏÔ×ŵķβ¿ÌØÕ÷Ö®Í⣬»¹±£´æÌåÖؼõÇáµÄ״̬¡£ÁÙ´²ÉÏ·¢Ã÷£¬COPD»¼ÕßµÄ̵ҺºÍѪÇåÖеİ×ϸ°û½éËØ-6 (IL-6)ˮƽ½Ï¸ß¡£Òò´Ë£¬¿Æѧ¼Òͨ¹ý¹¹½¨IL6ÇóýСÊó£¬ÓëÒ°ÉúÐ;ÙÐбÈÕÕ£¬ÑéÖ¤IL6¶ÔCOPD¼²²¡±¬·¢µÄÓ°Ïì¡£Ñо¿Ð§¹û·¢Ã÷£¬Ò°ÉúÐÍСÊóºÍ IL£¶ÇóýСÊóͬʱ¾ÙÐÐÏãÑÌÑÌÎí̻¶£¬IL6ÇóýСÊó¾ßÓнϵ͵ÄÌåÖØ£¬ÑªÇåÊÝËØˮƽºÍÖ¬·¾×éÖ¯ÖÊÁ¿£¬ÌáÐÑIL-6¿É×÷ΪÌåÖصĵ÷ÀíÒò×Ó[14]¡£
ÄÏÄ£ÉúÎï¿ÉÌṩCOPDÏà¹Ø»ùÒò¼°ÖÎÁưеãÇóýСÊóºÍÈËÔ´»¯Ð¡Êó£¬ÖúÁ¦COPDÏà¹ØÑо¿£¨¼ûÎÄÄ©±í3£©¡£
Ïø´Ñо¿Ä£×Ó
Ïø´ÓÖÃûÖ§Æø¹ÜÏø´¡£Ö§Æø¹ÜÏø´ÊÇÓɶàÖÖϸ°û¼°Ï¸°û×é·Ö¼ÓÈëµÄÂýÐÔÆøµÀÑ×Ö¢¡£ÏÖÔÚ¶ÔÏø´µÄ»ù´¡²¡ÒòÉв»¿ÉÍêÈ«Ïàʶ¡£î¾»¼Ïø´µÄ×î´óΣº¦ÒòËØÊÇÒÅ´«Ò׸ÐÐÔÓëÇéÐνӴ¥£¨ÎüÈë¿ÉÄÜÓÕ·¢¹ýÃô·´Ó¦»ò´Ì¼¤ÆøµÀµÄÎïÖʺͿÅÁ££©¶þÕßµÄÍŽᣬÕâÀàÎïÖʺͿÅÁ£°üÀ¨ÊÒÄÚ¹ýÃôÔ´£¨ÀýÈç¼ÒÍ¥³¾òý£©¡¢ÊÒÍâ¹ýÃôÔ´£¨ÀýÈ绨·Û£©ºÍÑ̲ÝÑÌÎíµÈ[15]¡£
ͼ7 Ïø´±¬·¢µÄÖ¢×´ºÍÖÂÃôÔ´
³¾òý£¨HDM£©ÊÇÎݳ¾¹ýÃôµÄÖ÷Òª¹ýÃôÔ´¡£ÔÚÒÑÓеÄÑо¿ÖÐ֤ʵÎú³¾òýÔÚÏø´µÄÉú³¤Öм°ÓÕ·¢ÆäËû¹ýÃôÐÔ¼²²¡£¨ÈçƤÑ׺ͱÇÑ×£©ÖÐÆðÖ÷Òª×÷ÓÃ[16]¡£HDMµÄ·à±ã¿ÅÁ£Öк¬ÓжàÖÖ¹ýÃôÔ£¬ÕâЩ¹ýÃôÔÊÇÈ«ÌìϹýÃôÐÔÏø´µÄÖ÷ÒªÓÕÒò£¬¿Éͨ¹ý¾Ö²¿Ê¹ÓÃHDM¿ª·¢¾ßÓÐÁÙ´²Ïà¹ØÒâÒåµÄСÊóÄ£×Ó¡£ÄÏÄ£ÉúÎï¿ÉÌṩ³¾òýÓÕµ¼µÄÏø´Ä£×Ó£¬ÏêϸÑéÖ¤Êý¾ÝÈçÏ¡£Í¼1ΪҰÉúÐÍC57BL/6СÊó¾³¾òýÓÕµ¼ºóÃâÒßϸ°ûÊýĿת±äµÄЧ¹û£¬±ÈÕÕ×éСÊóÏà±È£¬ÖÐÐÄÁ£Ï¸°û¡¢ÁÜ°Íϸ°ûºÍÊÈËáÐÔϸ°ûµÄÊýÄ¿ÓÐÏÔ×ŵÄÔöÌí¡£
ͼ8 C57BL/6СÊóÔÚ³¾òýÓÕµ¼ºóÖÖÖÖÃâÒßϸ°ûÊýÄ¿µÄת±ä
¾ø´ó´ó¶¼Ïø´»¼Õß±¬·¢Ê±¿Éͨ¹ý¿¹Ñס¢Æ½´µÈ¹Å°åÖÎÁÆÒ©Îï»ñµÃ¿ØÖÆ£¬µ«ÈÔÓв¿·Ö»¼ÕߵIJ¡ÇéÐèÒª½èÖúÈ«ÉíÓ¦Óø߼ÁÁ¿¼¤Ëزſɻº½â»òÈÔÎÞ·¨¿ØÖÆ£¬ÉõÖÁÍþвÉúÃü¡£½üÄêÀ´£¬Õë¶ÔÕâЩÄÑÖÎÐÔÖØÖ¢Ïø´£¬ÈËÃÇ¿ª·¢ÁËеİÐÏòÒ©Îï²¢Ó¦ÓÃÓÚÁÙ´²¡£ÏÖÔÚÒÑÉÏÊеİÐÏòÒ©ÓаÂÂíÖéµ¥¿¹£¨¿¹IgE£©£¬IL-5/IL-5Rµ¥¿¹¡£¸ßDZÁ¦ÔÚÑеÄÖضÈÏø´Ò©ÎïÓÐIL-4/IL-13µ¥¿¹£»TSLP¿¹Ì壻IL-33/ST-2µ¥¿¹µÈ¡£ÄÏÄ£ÉúÎï¿ÉÌṩÏìÓ¦°ÐµãµÄÈËÔ´»¯Ð¡Êó£¬ÖúÁ¦°ÐÏòÁ¢ÒìÒ©ÎïµÄÑз¢ºÍɸѡ£¨¼ûÎÄÄ©±í3£©¡£
·Î°©Ñо¿Ä£×Ó
·Î°©ÊÇÆðÔ´ÓÚÉÏƤ×éÖ¯µÄ¶ñÐÔÖ×Áö£¬ÔÚÎÒ¹úÖÖÖÖ¶ñÐÔÖ×ÁöÖз¢²¡ÂʺÍéæÃüÂʾùÅÅÃûµÚÒ»£¬ºÃ·¢ÄêËêÔÚ70ËêÒÔÉÏ£¬ÄÐÅ®·¢²¡ÂÊÖ®±ÈΪ2£º1¡£ÓÉÓÚ¿ÕÆøÎÛȾ¡¢·ÅÉäÐÔ̻¶ÒÔ¼°·Î²¿Õæ¾úѬȾµÈÔµ¹ÊÔÓÉ£¬Ê¹µÃ·Î°©µÄ·¢²¡ÂʺÍéæÃüÂʾþӲ»Ï¡£·Î°©Ö÷Òª·ÖΪ·ÇСϸ°û·Î°©£¨non small cell lung cancer, NSCLC£©ºÍСϸ°û·Î°©£¨small celllung cancer, SCLC£©£¬ÆäÖзÇСϸ°û·Î°©Ô¼Õ¼·Î°©µÄ80~85%[17]¡£ÔÚ·ÇСϸ°û·Î°©ÖУ¬·¢Ã÷Ðí¶àÇý¶¯Í»±ä£¬³£¼ûµÄÇý¶¯Í»±ä°üÀ¨KrasÍ»±ä¡¢EGFRÍ»±ä¡¢FGFR1À©Ôö¡¢ALKÖØÅÅ¡¢HER2Í»±ä¡¢METÀ©Ôö¡¢BRAFÍ»±äµÈ[17]¡£Ñо¿Ö°Ô±¶Ô·Î°©µÄ¶à¸öÍ»±ä¾ÙÐÐ̽ÌÖ£¬½«·Î°©Öз¢Ã÷µÄÍ»±ä½øÈëÒýÈ뵽СÊóÖУ¬´Ó¶ø»ñµÃ¶àÖÖÓÃÓÚÑо¿·Î°©±¬·¢ÓëתÒÆ»úÖÆ¡¢É¸Ñ¡ºÍÆÀ¼Û¿¹Ö×ÁöÒ©ÎïµÄ·Î°©Ä£×Ó¡£
±í2 ·ÇСϸ°û·Î°©ÖлùÒòÍ»±äƵÂʺÍÀàÐÍ[17]
ÏÖÔÚ¹ú¼ÊÉÏÓ¦ÓÃ×îÆÕ±éµÄ·Î°©¶¯ÎïÄ£×Ó¾ÍÊÇKras-LSL-G12DСÊóÄ£×Ó£¬¿ÉÒÔͨ¹ýÓë·ÎÉÏƤϸ°ûÌØÒìÐÔµÄCreת»ùÒòСÊóÔÓ½»À´ÊµÏÖKrasÍ»±äÌåµÄ¼¤»î£¬´Ó¶øµ¼Ö·ΰ©µÄ±¬·¢¡£ÄÏÄ£ÉúÎïÌṩµÄKras(LSL-G12D/+)СÊóƷϵÔÚKrasÍ»±ä»ùÒòµÄÉÏÓβåÈëÁËloxp-stop-loxpÖÕÖ¹ÐòÁУ¬ÆäÔÚûÓÐcreÖØ×éøµÄÌõ¼þÏÂÊDz»±í´ïµÄ¡£Cre½éµ¼µÄÖØ×é¿ÉÈ¥³ýÖÕÖ¹ÃÜÂë×Ó£¬Ê¹Ö°©»ùÒò±í´ï¡£½ÓÄÉÏÙ²¡¶¾ÔØÌåЯ´øCreѬȾ·Î²¿Ï¸°ûºó£¬µ¼Ö·ÎÖ×Áö±¬·¢µÄƵÂʺÜÊǸߣ¨Í¼8£©¡£
ͼ9 ½ÓÄÉÆø¹ÜÄÚ×¢ÉäµÄÒªÁ죬½«AAV-cre²¡¶¾×¢É䵽СÊó·Î²¿£¬3¸öÔºó¶ÔСÊó·Î²¿¾ÙÐÐCT¼ì²â£¬CTЧ¹ûÏÔʾÓÐÏÔ×ŵÄÖ×ÁöµÄÐγɡ£
±ðµÄ£¬ÎÒÃÇ»¹¿ÉÒÔÌṩKras(LSL-G12D/+)СÊóÖ×Áöϸ°ûȪԴµÄͬϵºÉÁöСÊóÄ£×Ó¡£Ö×Áöϸ°û¿ÉÔÚÊÜÌåСÊóÌåÄÚ¿ìËÙÔöÖ³£¨Èçͼ9£©¡£ºÉÁöСÊóÄ£×Ó¿ÉÌá¸ßÁÙ´²Ò©Ð§ÆÀ¼ÛʵÑé²Ù×÷µÄÇáÓ¯ÐÔ¡£
ͼ10 ºÉÁöСÊóÌåÄÚÖ×Áöϸ°ûÌå»ýËæʱ¼äÔöÌíµÄת±ä
¹ØÓڷΰ©µÄÏêϸÏÈÈݿɼûÍùÆÚÍÆÎÄ£º»ùÒò¹¤³ÌСÊó¼²²¡Ä£×ÓϵÁСª¡ª·Î°©Æª
ÄÏÄ£ÉúÎï·Î²¡¶¯ÎïÄ£×Ó
ÄÏÄ£ÉúÎï×ÔÖ÷¹¹½¨Á˶àÖÖ»ùÒòÐÞÊÎСÊ󣨱í3£©£¬¿ÉÒÔÓÃÓÚйڷÎÑס¢ÂýÐÔÛÕ±ÕÐÔ·ÎÑס¢Ïø´¡¢·Î°©µÈ¼²²¡µÄÑо¿ºÍÒ©Îïɸѡ¡£
±í3 ·Î²¿¼²²¡Ïà¹Ø¶¯ÎïÄ£×ÓÁбí
ÄÏÄ£ÉúÎïÉî¸û»ùÒò±à¼ÁìÓò£¬Ìṩȫ·½Î»Ä£Ê½ÉúÎïЧÀÍ£¬°üÀ¨»ùÒòÐÞÊÎÖÆÆ·Ä£×Ó¹©Ó¦¡¢¸öÐÔ»¯Ä£×Ó¶¨ÖÆ¡¢ËÇÑø·±Óý¡¢±íÐÍÆÊÎö¡¢Ò©Ð§ÆÀ¼ÛµÈ£¬Öª×ã²î±ðʵÑéÊÒÐèÇó¡£
Reference:
[1] https://www.nhlbi.nih.gov/health-topics/how-lungs-work
[2] Travaglini KJ, Nabhan AN, Penland L, et al. A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature. 2020 Nov;587(7835):619-625.
[3] https://www.ncbi.nlm.nih.gov/books/NBK557542/
[4] Hogan B.L.M. (2020) The Alveolar Stem Cell Niche of the Mammalian Lung. In: Nakanishi T., Baldwin H., Fineman J., Yamagishi H. (eds) Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension. Springer, Singapore. https://doi.org/10.1007/978-981-15-1185-1_2
[5] Schupp JC, Adams TS, Cosme C Jr, et al. Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung. Circulation. 2021 Jul 27;144(4):286-302. doi: 10.1161/CIRCULATIONAHA.120.052318.
[6]Gillich A, Zhang F, Farmer CG, Travaglini KJ, Tan SY, Gu M, Zhou B, Feinstein JA, Krasnow MA, Metzger RJ. Capillary cell-type specialization in the alveolus. Nature. 2020 Oct;586(7831):785-789. doi: 10.1038/s41586-020-2822-7.
[7] Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020 Sep 1;35(5):288-301.
[8] Jiang RD, Liu MQ, Chen Y, et al. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. Cell. 2020 Jul 9;182(1):50-58.e8.
[9]Wang C, Xu J, Yang L, Xu Y, et al; China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717.
[10]Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models[ J]. Am J Physiol Lung Cell Mol Physiol, 2008, 294(4): L612-L631£®
[11]ÀîÀöÇò, лÀö»ª, ËïÊ¥»ª. ÂýÐÔÛÕ±ÕÐԷμ²²¡¶¯ÎïÄ£×ÓµÄÑо¿Ï£Íû[J]. ÖÐÄÏ´óѧѧ±¨£ºÒ½Ñ§°æ, 2017, 42(9):6.
[12] Barreiro E, Wang X, Tang J. COPD: preclinical models and emerging therapeutic targets. Expert Opin Ther Targets. 2019 Oct;23(10):829-838. doi: 10.1080/14728222.2019.1667976. Epub 2019 Sep 20. PMID: 31512957.
[13] Wu M, Lai T, Jing D,et al. Epithelium-derived IL17A Promotes Cigarette Smoke-induced Inflammation and Mucus Hyperproduction. Am J Respir Cell Mol Biol. 2021 Jun 29.
[14] Pauwels NS, Bracke KR, Maes T, et al. The role of interleukin-6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease. Exp Lung Res. 2010 Oct;36(8):469-83.
[15]https://www.who.int/zh/news-room/fact-sheets/detail/asthma
[16]Tang W, Dong M, Teng F, Cui J, Zhu X, Wang W, Wuniqiemu T, Qin J, Yi L, Wang S, Dong J, Wei Y. Environmental allergens house dust mite-induced asthma is associated with ferroptosis in the lungs. Exp Ther Med. 2021 Dec;22(6):1483.
[17]Min-chul Kwon, Anton Berns. Mouse models for lung cancer. MOLECULAR ONCOLOGY 7 (2013) 165e177.